What clinical evidence supports semaglutide for weight loss in non-diabetic patients
Track these metrics weekly: Dose administered (mg, units, date, and time) Injection site (for rotation tracking) Side effects (type, severity 1 to 10, duration) Body weight (same time, same conditions each week) Body measurements (waist, hips, chest, if relevant) Appetite changes (subjective 1 to 10 scale) Energy levels (subjective 1 to 10 scale) Vial tracking (reconstitution date, volume remaining, expiration) This data tells you whether your dose is right, when to escalate, and whether the protocol is producing the desired outcomes
In their study the GSG-Index was found to be elevated in those with NAFLD, more elevated in NAFLD plus obesity, and highly correlated to liver enzymes
human clinical trials have not been completed.4-6,10